



Get With The Guidelines®-Stroke

Abby Loechler

February 20, 2024



What Patient Populations are entered?



Look Out For These Words...

- Cerebral Infarction
- Intracerebral Hemorrhage (nontraumatic)
- Ischemic Stroke
- Stroke
- Subarachnoid Hemorrhage (nontraumatic)
- Transient Ischemic Attack (TIA)

INCLUDE Patients:

- Initially admitted to the hospital for one of the diagnoses even if they later transfer or expire
- Directly admitted to nursing units within hospital without first being seen in ED (including patients with acute ischemic stroke who receive treatment at another hospital and are transferred to your hospital
- Who refuse treatment or who have Do Not Resuscitate orders
- Evaluated and treated in ED with the intention of being admitted, even if they expire, leave AMA, or are subsequently transferred to another acute care hospital prior to being admitted (including 'drip and ship' patients)





OPTIONAL:

- Patients who have an in-house stroke
- Patients who present with stroke-like symptoms but do not end up being diagnosed with a stroke or TIA
- Patients discharged from observational status with no inpatient admission
- Patients evaluated, treated and discharged from the ED (with no inpatient admission) to home or another location that is not an acute care hospital
- Patients with incidentally discovered infarcts (silent, subclinical, or prior CNS infarction)
- Elective CEAs

EXCLUDE:

Patients less than 18 years of age







Layers



What is a layer?

- Also known as a "form group" a layer in GWTG®-Stroke is a specific collection of data elements, form controls, queries, and reports (or other analytic mechanisms) that are only active when the layer is activated at a specific site.
- Layers can be applied to Stroke or Stroke Limited but will always default to the highest level of data abstraction required
 - (Example: If Coverdell is applied to a Stroke Limited form, the increased data collection for Coverdell will be used for all patients entered)
- A layer does not normally only apply data elements to a single "Tab" so referring to layer as a "Tab" is misleading and incorrect.
 - (Example: Calling the MER layer the "Advanced Stroke Tab")
- The active layers applied to a patient record can be reviewed by looking at the top of the case form.







Description	
Standard Get With The Guidelines® (GWTG®) data elements, form logic, and measures	
CDC Coverdell program data elements and form logic	
AHA GWTG® Diabetes data elements and measures (utilized for Target: Type 2 Diabetes Honor Roll)	
AHA GWTG® Prehospital data collection and measures	
AHA GWTG® data elements and measures	
AHA GWTG® Mechanical Endovascular Reperfusion data elements, form logic, and measures	
AHA GWTG® telestroke data elements, form logic, and measures	
Joint Commission Acute Stroke Ready (ASR) data elements, form logic, and measures	
Joint Commission Primary Stroke (STK, STK-OP-1, CSTK-01) data elements, form logic, and measures	
Joint Commission Comprehensive (CSTK) data elements, form logic, and measures	
Joint Commission Thrombectomy-Capable Stroke and Primary Stroke with Mechanical Thrombectomy data elements, form logic, and measures	
COMING SOON	
COMING SOON	

Active Group	Number of SEQIP hospitals participating
Coverdell	38
TJC ASR*	17
TJC STK*	30
TJC CSTK*	6
TSC / PSC with MT*	0





Certification Layer Details

Module	Option	Included Measures and Data Collection
Stroke	ASR Layer	STK-OP-1, ASR-OP-1, ASR-IP-1, ASR-IP-2, ASR-IP-3
Stroke	STK Layer	STK-1, STK-2, STK-3, STK-4, STK-5, STK-6, STK-8, STK-10, STK-OP-1, CSTK-01, STK-VOL-1
Stroke	TSC Layer	STK-1, STK-2, STK-3, STK-4, STK-5, STK-6, STK-8, STK-10, CSTK-01, CSTK-02, CSTK-05, CSTK-08, CSTK-09, CSTK-10, STK-OP-1, STK-VOL-1
Stroke	CSTK Layer	CSTK-01, CSTK-02, CSTK-03, CSTK-04, CSTK-05, CSTK-06, CSTK-07, CSTK-08, CSTK-09, CSTK-10, CSTK-11, CSTK-12
HF	ACHF Layer	ACHF-01, ACHF-02, ACHF-03, ACHF-04, ACHF-05, ACHF-06





TJC Acute Stroke Ready Measures

Prior to Transfer, No LVO

Standardized Performance Measures for Acute Stroke Ready Hospitals

Measure ID#	Measure Short Name	Measure Description
ASR-IP-1	Thrombolytic Therapy: Inpatient Admission	This measure captures the proportion of acute ischemic stroke patients who arrive at this hospital within 2 hours of time last known well and for whom IV alteplase was initiated at this hospital within 3 hours of time last known well.
ASR-OP-1	Thrombolytic Therapy: Drip and Ship	This measure captures the proportion of acute ischemic stroke patients who arrive at this hospital within 2 hours of time last known well and for whom IV alteplase was initiated at this hospital within 3 hours of time last known well (i.e., drip and ship patients).
ASR-IP-2	Antithrombotic Therapy By End of Hospital Day 2	This measure captures the proportion of ischemic stroke patients who had antithrombotic therapy administered by end of hospital day 2.
ASR-IP-3	Discharged on Antithrombotic Therapy	This measure captures the proportion of ischemic stroke patients prescribed antithrombotic therapy at hospital discharge.
STK-OP-1	Door to Transfer to Another Hospital	This measure reports the median time (in minutes) from hospital
	 Hemorrhagic Stroke 	arrival in the emergency department to transfer of a hemorrhagic stroke patient or an ischemic stroke patient to another hospital
	 Ischemic Stroke; No IV Alteplase Prior to Transfer, LVO and MER Eligible 	(stratified by stroke group).
Ischemic Stroke; No IV Alteplase Prior to Transfer, LVO and NOT MER Eligible		
	 Ischemic Stroke; No IV Alteplase Prior to Transfer, No LVO 	
Ischemic Stroke; IV Alteplase Prior to Transfer, LVO and MER Eligible Ischemic Stroke; IV Alteplase Prior to Transfer, LVO and NOT MER Eligible Ischemic Stroke; IV Alteplase		
	Prior to Transfer, LVO and NOT	
	 Ischemic Stroke; IV Alteplase 	





TJC Primary Stroke Measures

Standardized Performance Measures for Primary Stroke Centers

Measure ID#	Measure Short Name	Measure Description
CSTK-01	National Institutes of Health Stroke Scale (NIHSS) Score Performed for Ischemic Stroke Patients	This measure captures the proportion of ischemic stroke patients for whom an initial NIHSS score is performed prior to any acute recanalization therapy (i.e., IV alteplase therapy, or IA alteplase therapy, or mechanical endovascular reperfusion therapy) in patients undergoing recanalization therapy and documented in the medical record, OR documented within 12 hours of arrival at the hospital emergency department for patients who do not undergo recanalization therapy.
STK-OP-1	Door to Transfer to Another Hospital	This measure reports the median time (in minutes) from hospital
	 Hemorrhagic Stroke 	arrival in the emergency department to transfer of a hemorrhagic stroke patient or an ischemic stroke patient to another hospital
	 Ischemic Stroke; No IV Alteplase Prior to Transfer, LVO and MER Eligible 	(stratified by stroke group).
 Ischemic Stroke; No IV Alteplase Prior to Transfer, LVO and NOT MER Eligible 		
	 Ischemic Stroke; No IV Alteplase Prior to Transfer, No LVO 	
 Ischemic Stroke; IV Alteplase Prior to Transfer, LVO and MER Eligible 		
	 Ischemic Stroke; IV Alteplase Prior to Transfer, LVO and NOT MER Eligible 	
	Ischemic Stroke; IV Alteplase Prior to Transfer, No LVO	

Measure ID#	Measure Short Name	Measure Description
STK-1	Venous Thromboembolism (VTE) Prophylaxis	This measure captures the proportion of ischemic or hemorrhagic stroke patients who received VTE prophylaxis or have documentation why no VTE prophylaxis was given the day of or the day after hospital admission.
STK-2	Discharged on AntithromboticTherapy	This measure captures the proportion of ischemic stroke patients prescribed antithrombotic therapy at hospital discharge.
STK-3	Anticoagulation Therapy for Atrial Fibrillation/Flutter	This measure captures the proportion of ischemic stroke patients with atrial fibrillation/flutter who are prescribed anticoagulation therapy at hospital discharge.
STK-4	Thrombolytic Therapy	This measure captures the proportion of acute ischemic stroke patients who arrive at this hospital within 2 hours of time last known well and for whom IV alteplase was initiated at this hospital within 3 hours of time last known well.
STK-5	Antithrombotic Therapy By End of Hospital Day 2	This measure captures the proportion of ischemic stroke patients who had antithrombotic therapy administered by end of hospital day 2.
STK-6	Discharged on Statin Medication	This measure captures the proportion of ischemic stroke patients who are prescribed statin medication at hospital discharge.
STK-8	Stroke Education	This measure captures the proportion of ischemic or hemorrhagic stroke patients or their caregivers who were given educational materials during the hospital stay addressing all of the following: activation of emergency medical system, need for follow-up after discharge, medications prescribed at discharge, risk factors for stroke, and warning signs and symptoms of stroke.
STK-10	Assessed for Rehabilitation	This measure captures the proportion of ischemic or hemorrhagic stroke patients who were assessed for rehabilitation services.
STK-VOL-1	Ischemic Stroke Patients	This measure captures the proportion of patients with ischemic
	Who Receive Mechanical Endovascular Reperfusion Therapy	stroke who receive mechanical endovascular reperfusion therapy.





Additional Measures for Primary Stroke Centers Performing Mechanical Thrombectomy Procedures

Measure ID#	Measure Short Name	Measure Description
CSTK-02	Modified Rankin Score (mRS) at 90 Days (Process Measure)	This measure captures the proportion of ischemic stroke patients treated with intra-venous (IV) or intra-arterial (IA) alteplase therapy or who undergo mechanical endovascular reperfusion therapy for whom a 90 day (≥75 days and ≤105 days) mRS is obtained via telephone or in-person.
CSTK-05	Hemorrhagic Transformation (Overall Rate) • IV t-PA Only • IA t-PA or MER	This measure captures the proportion of ischemic stroke patients who develop a symptomatic intracranial hemorrhage (i.e., clinical deterioration ≥ 4 point increase on NIHSS and brain image finding of parenchymal hematoma, or subarachnoid hemorrhage, or intraventricular hemorrhage) within (≤) 36 hours after the onset of treatment with intra-venous (IV) or intra-arterial (IA) alteplase therapy, or mechanical endovascular reperfusion procedure (i.e., mechanical endovascular thrombectomy with a clot retrieval device) (stratified by type of therapy).
CSTK-08	Thrombolysis in Cerebral Infarction (TICI) Post-Treatment Reperfusion Grade	This measure captures the proportion of ischemic stroke patients with a post-treatment reperfusion grade of TICI 2B or higher in the vascular territory beyond the target arterial occlusion at the end of mechanical endovascular reperfusion therapy.
CSTK-09	Arrival Time to Skin Puncture	This measure reports the median time (in minutes) from hospital arrival to the time of skin puncture to access the artery (e.g., brachial, carotid, femoral, radial) selected for endovascular treatment (EVT) of acute ischemic stroke.





TJC Thrombectomy-Capable Stroke Measures

Standardized Performance Measures for Thrombectomy-Capable Stroke Centers

Measure ID#	Measure Short Name	Measure Description
CSTK-01	National Institutes of Health Stroke Scale (NIHSS) Score Performed for Ischemic Stroke Patients	This measure captures the proportion of ischemic stroke patients for whom an initial NIHSS score is performed prior to any acute recanalization therapy (i.e., IV alteplase therapy, or IA alteplase therapy, or mechanical endovascular reperfusion therapy) in patients undergoing recanalization therapy and documented in the medical record, OR documented within 12 hours of arrival at the hospital emergency department for patients who do not undergo recanalization therapy.
CSTK-02	Modified Rankin Score (mRS) at 90 days (process measure)	This measure captures the proportion of ischemic stroke patients treated with intra-venous (IV) or intra-arterial (IA) alteplase therapy or who undergo mechanical endovascular reperfusion therapy for whom a 90 day ($\!\geq\!75$ days and $\!\leq\!105$ days) mRS is obtained via telephone or in-person.
CSTK-05	Hemorrhagic Transformation (Overall Rate) • IV t-PA Only • IA t-PA or MER	This measure captures the proportion of ischemic stroke patients who develop a symptomatic intracranial hemorrhage (i.e., clinical deterioration ≥ 4 point increase on NIHSS and brain image finding of parenchymal hematoma, or subarachnoid hemorrhage, or intraventricular hemorrhage) within (\leq) 36 hours after the onset of treatment with intra-venous (IV) or intra-arterial (IA) alteplase therapy, or mechanical endovascular reperfusion procedure (i.e., mechanical endovascular thrombectomy with a clot retrieval device) (stratified by type of therapy).
CSTK-08	Thrombolysis in Cerebral Infarction (TICI) Post-Treatment Reperfusion Grade	This measure captures the proportion of ischemic stroke patients with a post-treatment reperfusion grade of TICl 2B or higher in the vascular territory beyond the target arterial occlusion at the end of mechanical endovascular reperfusion therapy.
CSTK-09	Arrival Time to Skin Puncture Transfers Direct Arrivals	This measure reports the median time (in minutes) from hospital arrival to the time of skin puncture to access the artery (e.g., brachial, carotid, femoral, radial) selected for endovascular treatment (EVT) of acute ischemic stroke.

Measure ID#	Measure Short Name	Measure Description
STK-1	Venous Thromboembolism (VTE) Prophylaxis	This measure captures the proportion of ischemic or hemorrhagic stroke patients who received VTE prophylaxis or have documentation why no VTE prophylaxis was given the day of or the day after hospital admission.
STK-2	Discharged on AntithromboticTherapy	This measure captures the proportion of ischemic stroke patients prescribed antithrombotic therapy at hospital discharge.
STK-3	Anticoagulation Therapy for Atrial Fibrillation/Flutter	This measure captures the proportion of ischemic stroke patients with atrial fibrillation/flutter who are prescribed anticoagulation therapy at hospital discharge.
STK-4	Thrombolytic Therapy	This measure captures the proportion of acute ischemic stroke patients who arrive at this hospital within 2 hours of time last known well and for whom IV alteplase was initiated at this hospital within 3 hours of time last known well.
STK-5	Antithrombotic Therapy By End of Hospital Day 2	This measure captures the proportion of ischemic stroke patients who had antithrombotic therapy administered by end of hospital day 2.
STK-6	Discharged on Statin Medication	This measure captures the proportion of ischemic stroke patients who are prescribed statin medication at hospital discharge.
STK-8	Stroke Education	This measure captures the proportion of ischemic or hemorrhagic stroke patients or their caregivers who were given educational materials during the hospital stay addressing all of the following: activation of emergency medical system, need for follow-up after discharge, medications prescribed at discharge, risk factors for stroke, and warning signs and symptoms of stroke.
STK-10	Assessed for Rehabilitation	This measure captures the proportion of ischemic or hemorrhagic stroke patients who were assessed for rehabilitation services.
STK-VOL-1	Ischemic Stroke Patients	This measure captures the proportion of patients with ischemic
	Who Receive Mechanical	stroke who receive mechanical endovascular reperfusion therapy.
	Endovascular Reperfusion Therapy	





TJC Comprehensive Stroke Measures

Standardized Performance Measures for Comprehensive Stroke Centers

Joint Commission Quality Measures for Disease-Specific Care Certification

Measure ID#	Measure Short Name	Measure Description
CSTK-01	National Institutes of Health Stroke Scale (NIHSS) Score Performed for Ischemic Stroke Patients	This measure captures the proportion of ischemic stroke patients for whom an initial NIHSS score is performed prior to any acute recanalization therapy (i.e., IV alteplase therapy, or IA alteplase therapy, or mechanical endovascular reperfusion therapy) in patients undergoing recanalization therapy and documented in the medical record, OR documented within 12 hours of arrival at the hospital emergency department for patients who do not undergo recanalization therapy.
CSTK-03	Severity Measurement Performed for SAH and ICH Patients (Overall Rate) • SAH • ICH	This measure captures the proportion of subarachnoid hemorrhage (SAH) and intracerebral hemorrhage (ICH) stroke patients for whom a severity measurement (i.e., Hunt and Hess Scale for SAH patients or ICH Score for ICH patients) is performed prior to surgical intervention (e.g. clipping, coiling, or any surgical intervention) in patients undergoing surgical intervention and documented in the medical record; OR documented within 6 hours of arrival at the hospital emergency department for patients who do not undergo surgical intervention (stratified by stroke diagnosis).
CSTK-04	Procoagulant Reversal Agent Initiation for Intracerebral Hemorrhage (ICH)	This measure captures the proportion of intracerebral hemorrhage (ICH) stroke patients with an INR value > 1.4 at hospital arrival who are treated with a procoagulant reversal agent (i.e., fresh frozen plasma, recombinant factor VIIa, prothrombin complex concentrates).
CSTK-05	Hemorrhagic Transformation (Overall Rate) • IV t-PA Only • IA t-PA or MER	This measure captures the proportion of ischemic stroke patients who develop a symptomatic intracranial hemorrhage (i.e., clinical deterioration ≥ 4 point increase on NIHSS and brain image finding of parenchymal hematoma, or subarachnoid hemorrhage, or intraventricular hemorrhage) within (≤) 36 hours after the onset of treatment with intra-venous (IV) or intra-arterial (IA) alteplase therapy, or mechanical endovascular reperfusion procedure (i.e., mechanical endovascular thrombectomy with a clot retrieval device) (stratified by type of therapy).
CSTK-06	Nimodipine Treatment Administered	This measure captures the proportion of subarachnoid hemorrhage (SAH) patients for whom nimodipine treatment was administered within 24 hours of arrival at this hospital.
CSTK-08	Thrombolysis in Cerebral Infarction (TICI) Post-Treatment Reperfusion Grade	This measure captures the proportion of ischemic stroke patients with a post-treatment reperfusion grade of TiCl 2B or higher in the vascular territory beyond the target arterial occlusion at the end of mechanical endovascular reperfusion therapy.
CSTK-09	Arrival Time to Skin Puncture Transfers Direct Arrivals	This measure reports the median time (in minutes) from hospital arrival to the time of skin puncture to access the artery (e.g., brachial carotid, femoral, radial) selected for endovascular treatment (EVT)

of acute ischemic stroke.

Measure ID#	Measure Short Name	Measure Description
CSTK-10	Modified Rankin Score (mRS) at 90 Days: Favorable Outcome IV t-PA Only - Independent IV t-PA Only - Dependent MER - Independent MER - Dependent	This measure captures the proportion of ischemic stroke patients treated with intra-venous (IV) alteplase therapy or who undergo mechanical endovascular reperfusion therapy and have a mRS less than or equal to 2 at 90 days (≥75 days and ≤105 days).
CSTK-11	Rate of Rapid Effective Reperfusion From Hospital Arrival	This measure captures the proportion of ischemic stroke patients with
	Tolli Tospital Allival	a large vessel cerebral occlusion (i.e., internal carotid artery (ICA) or ICA terminus (T-lesion); T-occlusion), middle cerebral artery (MCA) M1 or M2, basilar artery) who receive mechanical endovascular reperfusion (MER) therapy within 120 minutes (>/= 0 min. and = 150 min.) of hospital arrival and achieve TICI 2B or higher at the end of treatment.</td
CSTK-12	Rate of Rapid Effective Reperfusion From Skin Puncture	This measure captures the proportion of ischemic stroke patients with a large vessel cerebral occlusion (i.e., internal carotid artery (ICA) or ICA terminus (T-lesion; T-occlusion), middle cerebral artery (MCA) M1 or M2, basilar artery) who receive mechanical endovascular reperfusion (MER) therapy and achieve TICI 2B or higher less than (<) or equal to 60 minutes from the time of skin puncture.
STK-1	Venous Thromboembolism (VTE) Prophylaxis	This measure captures the proportion of ischemic or hemorrhagic stroke patients who received VTE prophylaxis or have documentation why no VTE prophylaxis was given the day of or the day after hospital admission.
STK-2	Discharged on Antithrombotic Therapy	This measure captures the proportion of ischemic stroke patients prescribed antithrombotic therapy at hospital discharge.
STK-3	Anticoagulation Therapy for Atrial Fibrillation/Flutter	This measure captures the proportion of ischemic stroke patients with atrial fibrillation/flutter who are prescribed anticoagulation therapy at hospital discharge.
STK-4	Thrombolytic Therapy	This measure captures the proportion of acute ischemic stroke patients who arrive at this hospital within 2 hours of time last known well and for whom IV alteplase was initiated at this hospital within 3 hours of time last known well.
STK-5	Antithrombotic Therapy By End of Hospital Day 2	This measure captures the proportion of ischemic stroke patients who had antithrombotic therapy administered by end of hospital day 2.
STK-6	Discharged on Statin Medication	This measure captures the proportion of ischemic stroke patients who are prescribed statin medication at hospital discharge.
STK-8	Stroke Education	This measure captures the proportion of ischemic or hemorrhagic stroke patients or their caregivers who were given educational materials during the hospital stay addressing all of the following: activation of emergency medical system, need for follow-up after discharge, medications prescribed at discharge, risk factors for stroke, and warning signs and symptoms of stroke.
STK-10	Assessed for Rehabilitation	This measure captures the proportion of ischemic or hemorrhagic stroke patients who were assessed for rehabilitation services.



